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It has been widely accepted that estrogen
activities are mediated either genomically
through binding of specific intracellular
receptors located within target cells or
through local membrane types of mecha-
nisms at the cell surface (1,2). A number of
environmental agents recognized as environ-
mental estrogens or simply xenoestrogens
interact at the estrogen receptor level. As a
result, public and scientiﬁc interests regard-
ing estrogenic functions have focused their
attention on both the toxic and biologically
beneﬁcial actions of some classes of environ-
mental chemicals. A member of this class of
environmental estrogen is the industrial phe-
nolic chemical bisphenol A (BPA). Such a
xenoestrogen is widely used in the manufac-
ture of polycarbonate plastics, epoxy resins
for lining food cans, and dental sealants, and
as a stabilizing agent in plastics such as
polyvinyl chloride (3,4). These man-made
chemicals, because of their leaching from
numerous reservoirs, can enter the body by
ingestion or adsorption and mimic the
actions of estrogens. Earlier studies revealed
that when derivatives of BPA, such as the
well-known diglycidyl ether of BPA, com-
monly used in food packaging, come into
contact with food products, the residual
monomer solvents and/or additives in the
polymer may migrate to the nourishing
component (3,5). Thus, major attention has
been directed toward the potentially toxic
steroidal actions of this environmental estro-
gen as displayed by some reproductive
malformations of offspring after maternal
exposure to BPA (6,7). 
Despite the 1,000-fold less potent activ-
ity of BPA with respect to that of estradiol
(E2), it is still able to mimic E2 biological
actions such as vaginal corniﬁcation (7) and
growth and differentiation of the mammary
gland (8). Consequently, it appears that not
only estrogens but also xenoestrogen deriva-
tives have important and diverse pleiotropic
actions in both reproductive and nonrepro-
ductive tissues. In this context, the growth
hormone system, and above all somatostatin
(SRIF) play a crucial role in neurosecretory
function (9) at the encephalic level, espe-
cially in relation to tissue content (10),
which is still an unresolved facet of BPA
effects. SRIF is widely distributed in the
mammalian brain and is contained in short
interneurons plus projecting neuronal path-
ways. To date, five distinct receptor
subtypes, designated as sst1–5, have been
identiﬁed as a family of G protein–coupled
receptors (11). Of these five receptor sub-
types, sst2, which is densely distributed in
the various brain regions, is considered to be,
from a functional point of view, one of the
most important cerebral subtypes (12,13).
This subtype also promotes neurotransmis-
sion actions, probably through the involve-
ment of both the high and low receptor-
binding states (14), as revealed by the suc-
cessful neurobiological functions of sst2,
especially in the presence of E2 (15,16). 
Recently, the subtype sst2 has provided a
speciﬁc analgesic type of behavioral response
similar to that noted for another major neu-
ronal inhibitory system, the hetero-
oligomeric γ-aminobutyric acid (GABA)
type A receptor (17). This receptor system,
which constitutes nearly 60% of neuronal
synapses, consists of at least seven classes of
genes that encode for the following subunits:
α, β, γ, δ, ε, π, ρ. Among this long list of
subunits, the first, which is involved in the
assembly of the other sequences and also
determines the overall biophysical and phar-
macological properties of the GABA type A
receptor (18), has been chosen for this study.
On the basis of the specific interactions
between sex steroids and sst2 receptor sub-
type, as well as the colocalization of estrogen
receptors and GABA type A neurons (19),
we investigated whether the binding activity
of sst2 alone or in the presence of some α
GABA type A receptor subunit isoforms
occurs in an estrogenic fashion in the pres-
ence of BPA. These relationships may bring
us closer to identifying molecular receptor
activities operating at the brain level after
exposure to BPA. 
This article is part of the monograph Impact of
Endocrine Disruptors on Brain Development and
Behavior.
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Endocrine Disruptors
Recently, considerable interest has been aroused by the specific actions of bisphenol A (BPA).
The present investigation represents a ﬁrst study dealing with the interaction of BPA with the
biologically more active somatostatin receptor subtype (sst2) in the rat limbic circuit. After treat-
ing pregnant female Sprague-Dawley rats with two doses (400 µg/kg/day; 40 µg/kg/day) of BPA,
the binding activity of the above receptor subtype was evaluated in some limbic regions of the
offspring. The higher dose proved to be the more effective one, as demonstrated by the elevated
affinity of sst2 with its specific radioligand, [125I]-Tyr0somatostatin-14. The most dramatic
effects of BPA on sst2 levels occurred at the low-afﬁnity states of such a subtype in some telen-
cephalic limbic areas of postnatal rats (10 days of age; postnatal day [PND] 10). These included
lower (p < 0.05) sst2 levels in the gyrus dentate of the hippocampus and basomedial nucleus of
the amygdala; signiﬁcantly higher (p < 0.01) levels were observed only for the high-afﬁnity states
of the periventricular nucleus of the hypothalamus. A similar trend was maintained in PND 23
rats with the exception of much lower levels of the high-affinity sst2 receptor subtype in the
amygdala nucleus and ventromedial hypothalamic nucleus. However, greater changes produced
by this environmental estrogen were reported when the binding activity of sst2 was checked in
the presence of the two more important selective agonists (zolpidem and Ro 15-4513) speciﬁc for
the α-containing γ-aminobutyric acid (GABA) type A receptor complex. In this case, an even
greater potentiating effect (p < 0.001) was mainly obtained for the low-afﬁnity sst2 receptor sub-
type in PND 10 animals, with the exception of the high-afﬁnity type in the ventromedial hypo-
thalamic nucleus and gyrus dentate. These results support the contention that an sst2 subtype
α–containing GABA type A receptor system might represent an important neuromediating sta-
tion capable of promoting estrogenlike mechanisms of BPA, especially during the early develop-
mental phases. Key words: autoradiography, brain, development, GABA, rats, somatostatin
receptors, xenoestrogen. Environ Health Perspect 110(suppl 3):397–402 (2002).
http://ehpnet1.niehs.nih.gov/docs/2002/suppl-3/397-402facciolo/abstract.html
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Materials and Methods
Animals
Sexually mature Sprague-Dawley female rats
(200–250 g) were purchased from Charles
River (Como, Italy), caged individually,
housed in the Cellular Biology Department
(University of Calabria, Cosenza, Italy) stab-
ularium, and maintained on a 12-hr
dark/12-hr light schedule (lights on 14:00–
2:00 hr). Animal maintenance and experi-
mental procedures were in accordance with
the Guide for Care and Use of Laboratory
Animals (20). Efforts were made to minimize
animal suffering and reduce the number of
specimens used.
Bisphenol A Administration
Thirty-two 60-day-old female rats were sub-
divided into three experimental groups in
which four females were housed per cage
with stainless steel wire lids for 3 days for
acclimation purposes. Afterward these rats
received either 40 µg/kg/day BPA (lBPA;
Sigma Chemical, Milan, Italy) po or 400
µg/kg/day BPA (hBPA) po dissolved in
arachis oil and were compared with controls
that consisted of only arachis oil (OIL)-
treated rats for 10 days. BPA was given
orally because this route of exposure is more
relevant to human exposure. These two
doses of BPA were chosen on the basis of
their capability to promote evident morpho-
metrical changes in offspring (21,22), as well
as to represent the concentrations that may
be released when resins for lining food cans
and dental sealants come into contact with
food products. During this treatment period,
a sexually mature Sprague-Dawley male was
introduced into each cage and left there for 5
days. Pregnant females were isolated in sin-
gle cages; at birth, litters were culled to eight,
and pups (one per litter) were randomly
assigned to dams of the same treatment. For
the next 23 days, while the dam reared her
foster pups within the same cage, she contin-
ued to receive the same treatment until the
weaning of the pups at postnatal day (PND)
23, to assure exposure both via the placenta
and lactation. During this period PND 10
rats from the treatment groups lBPA (n = 6),
hBPA (n = 7), and OIL (n = 4) were decapi-
tated and their brains quickly removed for
sst2 receptor autoradiography. Others were
decapitated at PND 23 (lBPA, n = 7; hBPA,
n = 7; OIL, n = 5). 
Effects of Bisphenol A on Interaction
between sst2 and α-Containing
GABA Type A Receptor
Receptor autoradiography approaches were
used to identify the relationship between
BPA, sst2, and GABA type A receptor
activity. For this part, the brain of
BPA-treated rats at PND 10 (hBPA, n = 5;
lBPA, n = 6) and PND 23 (hBPA, n = 6;
lBPA, n = 4), along with their respective
controls (n = 4; n=5), were used. The
autoradiographic analyses of the SRIF sub-
type sst2 were conducted on posterior lim-
bic brain sections (12 mm) according to
previously described methods (23), plus
modifications. In such a trial it was impor-
tant that brain tissue was prewashed 3
times at room temperature in 50 mM Tris-
HCl buffer, pH 7.4, with one of these
washes (30 min) performed in the presence
of 10–5 M guanosine 5´-triphosphate
(GTP) (Sigma Chemical) to allow the dis-
sociation of endogenous ligand as well as
the binding specificity of this class of
G-coupled receptor subtype (sst2) with
respect to those considered the deglycosy-
lated type (24). Subsequently, slices were
incubated for 1 hr at the same temperature
and in the same buffer containing 0.5%
bovine serum albumin and varying concen-
trations (5–500 pM) of [125I]-Tyr0-
SRIF14 (81.4 TBq/mmole; New England
Nuclear Division, Milan, Italy) ± 1 mM
cold SRIF14 (nonspecific binding). The
selection of this radioligand was based on
its preferential affinity toward sst2 receptor
subtypes (13). After an exposure period of
18 days at room temperature, autoradi-
ographic films (Hyperfilm; Amersham,
Milan, Italy) of dried sections plus relative
standards were evaluated with a Zeiss
VIDAS image analyzer (Zeiss, Milan,
Italy). Labeled sections were stained with
cresyl violet acetate to identify the different
posterior limbic areas.
To evaluate interaction of the sst2 recep-
tor subtypes with certain α GABA type A
receptor subunits, adjacent brain slices were
incubated in a fashion similar to that used in
the saturation study. This time incubation
was handled, as determined in a previous
study (14), in the presence of the best [125I]-
Tyr0-SRIF14 afﬁnity state (25 pM) and dif-
ferent concentrations (5 nM–500 µM) of the
selective agonists (the imidazopyridine zolpi-
dem [Synthelabo Recherche, Paris, France]
or the imidazobenzodiazepinone Ro 15-4513
[Hoffmann-LaRoche, Basel, Switzerland]), or
a selective agonist of the GABA type A com-
plex, isoguvacine (ICN Biomedicals, Milan,
Italy). The former two drugs, speciﬁc for the
a subunit, are noted for their strong analgesic
actions, whereas the latter, which is speciﬁc
for the β subunit, was included as a means of
receptor subunit specificity (25). The levels
of sst2 induced by the higher dose of BPA
with respect to arachis-treated animals in rats
of both 10 (n = 12) and 23 days of age (n =
13) in the presence of the GABA type A
selective agonists were expressed as a ratio
with respect to the same treatment groups in
the absence of the selective agonists. The
choice of hBPA treatment group and the
concentration of [125I]-Tyr0-SRIF14 to apply
in the in vitro autoradiographic evaluation
were determined by both saturation binding
and wipe assay evaluations (26) of posterior
brain regions.
Statistical Analysis
Results were reported as means ± SEM for
all trials. For the receptor binding study,
Scatchard analysis of saturation binding
data, which were ﬁtted by a one-site and/or
two-site model [based on the signiﬁcance of
extra-sum square using LIGAND program
(27)], supplied relative affinity states and
maximal receptor binding densities. A two-
tailed Student’s t-test was applied for BPA
effects on sst2 receptor activity. One-way
analysis of variance (ANOVA) was also used
for a GABA type A-sst2 receptor differences,
followed where necessary by Newman-Keuls
multiple range test. Signiﬁcance was checked
when the p value was less than 0.05. 
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Figure 1. Ligand-binding assay. (A) Saturation
curves of [125I]-Tyr0-SRIF14 (pM) versus specific
binding level (fmol/mg protein) ± SEM in posterior
brain regions of rats treated with lBPA (n = 6) and
hBPA (n = 5) compared with those treated with OIL
(n = 5) were obtained by wipe assay procedures
using different concentrations (5–500 pM) of the
radioligand, as reported in “Materials and
Methods.” (B) The linear Scatchard plots of spe-
ciﬁc binding level (fmol/mg protein) versus speciﬁc
binding levels/[125I]-Tyr0-SRIF14 (fmol/mg
protein/pM) ± SEM enabled us to calculate the
negative slope that provided the mean dissociation
constant, while the intercept of the curve at the
abscissa provided the maximal number of binding
sites. Evaluation of saturation-binding study sup-
plied similar results in ﬁve separate tests.
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Results
Effects of BPA on Interaction
between sst2 and α-Containing
GABA Type A Receptor 
This study dealing with early cerebral activi-
ties of the environmental estrogen BPA via
the sst2 receptor subtypes in some limbic
areas of the rat displayed a fairly speciﬁc and
stable binding activity, as shown by the rep-
resentative saturation curve of posterior lim-
bic regions of rats 23 days of age (Figure 1).
Additionally, comparison of the two BPA
doses (40 and 400 µg/kg/day) permitted us
to ameliorate the heterogeneous and stable
binding activity of [125I]-Tyr0-SRIF14 to its
preferred receptor subtype (sst2), especially
in the case of the latter dose, which is
regarded as the most effective dose capable
of disrupting any endocrine function (28).
For this purpose, and because of the weaker
affinity of the radioligand [125I]-Tyr0-
SRIF14 toward sst2 subtype in the presence
of lBPA, only hBPA was tested for binding
activities with sst2 in the posterior limbic
areas of animals 10 and 23 days of age. The
labeling of this receptor subtype with its
specific radioligand provided a heteroge-
neous and uniform type of binding in the
different posterior limbic areas, as shown in
the representative autoradiograms (Figure 2).
When the binding parameters of the sst2
subtype were identiﬁed by Scatchard analy-
sis, it was possible to observe two different
binding affinities under the influence of
hBPA (high afﬁnity ≤ 75 pM; low afﬁnity ≥
75 ≤ 500 pM), as reported in previous work
for another rodent study (14). 
The variations of sst2 binding parameters
after treatment with this xenoestrogen
proved to be primarily of a mixed nature in
the telencephalic regions of both PND 10
and PND 23 rats. In the former animals,
hBPA was responsible for the diminished
levels of the low-affinity sst2 receptors (p <
0.05) in the gyrus dentate (GD) of the hip-
pocampus and basomedial nucleus of the
amygdala (Bm) (Figure 3B). A similar varia-
tion, this time of the enhanced type, was
obtained for the stratum radiatum lacuno-
sum CA1 layer of the hippocampus (RAD).
As far as the high-afﬁnity type of sst2 recep-
tors were concerned, BPA significantly
enhanced (p < 0.01) the levels of this afﬁnity
type in the hypothalamus and speciﬁcally the
periventricular nucleus (Pe) (Figure 3A). A
comparable trend was reported for mainly
the same limbic areas of PND 23 animals
(Figure 4). Diminished (p < 0.05) and even
significantly (p < 0.001) lower levels of the
low-affinity type of sst2 receptor were
registered in the cortico-medial (Co-Me)
nucleus of the amygdala and RAD, respec-
tively (Figure 4B). In the high-afﬁnity type,
signiﬁcantly diminished levels were found in
Bm and the ventromedial hypothalamic
nucleus (VMN), whereas higher levels were
observed only in the GD (Figure 4A) of the
same animals.
Next, the influence of BPA on cerebral
sst2 binding activity in the presence of the
selective agonists of the α-containing GABA
type A receptor system was examined to
determine the role of this other major neu-
ronal system on BPA-dependent effects.
Displacement activities of [125I]-Tyr0-
SRIF14 binding by these two agonists
(zolpidem and Ro 15-4513) resulted in the
shifting of the curve to the left, which corre-
sponds to a greater affinity for sst2 receptor
subtype compared with the other GABA
type A agonist (Figure 5). Consequently,
incubation of the same brain regions with
these two selective agonists accounted for
even greater potentiating activities of BPA
on the two sst2 afﬁnity states, especially the
low-afﬁnity type in postnatal animals. When
the effects of BPA in the presence of the two
α-containing GABA type A agonists were
compared with those in the absence of the
two agonists (Figures 6, 7), higher levels of
the low-afﬁnity sst2 receptor occurred in the
Pe and GD of PND 10 animals, whereas sig-
niﬁcantly higher Ro 15-4513–induced levels
were reported for both the Bm and VMN
(Figure 6B). In the same biological stage, a
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Figure 3. BPA-dependent binding activity varia-
tions of the sst2 receptor subtype in PND-10 rats.
[125I]-Tyr0-SRIF14 binding levels (fmol/mg pro-
tein; χ – ± SEM) to the high (A) and low (B) affinity
state of sst2 receptor subtypes were evaluated
in some limbic areas of PND-10 rats (n = 10)
treated with either hBPA or OIL, as described in
“Materials and Methods.” Mean values in each
brain region of the same treatment group were
analyzed using a two-tailed Student’s t-test.
*p<   0.05; **p < 0.01. 
Figure 2. Representative binding autoradiograms
of posterior brain regions. Abbreviations: HP,
hippocampus; VL, ventral lateral posterior thala-
mic nucleus. (i) A heterogeneous binding activity
of the sst2 receptor subtype was obtained in some
limbic areas of PND-23 rats when the posterior
brain regions of (A) OIL-treated and (B) hBPA-
treated animals were incubated in the presence
of 25 pM [125I]-Tyr0-SRIF14, as described in
“Materials and Methods.” This binding pattern
was compared with that of their respective (ii)
nonspeciﬁc binding autoradiograms. Bar = 4 mm.
ii i
ii i
A
B
4 mm
400
350
300
250
200
150
100
50
0
S
p
e
c
i
f
i
c
 
b
i
n
d
i
n
g
 
l
e
v
e
l
(
f
m
o
l
/
m
g
 
p
r
o
t
e
i
n
)
VMN Pe GD RAD Co-Me Bm
VMN Pe GD RAD Co-Me Bm
S
p
e
c
i
f
i
c
 
b
i
n
d
i
n
g
 
l
e
v
e
l
(
f
m
o
l
/
m
g
 
p
r
o
t
e
i
n
)
A OIL
hBPA
250
200
150
100
50
0
OIL
hBPA
B
*
**
*
*
Figure 4. BPA-dependent binding activity varia-
tions of the sst2 receptor subtype in PND-23 rats.
[125I]-Tyr0-SRIF14 binding (fmol/mg protein; χ – +
SEM) to the (A) high-affinity and (B) low-affinity
state of sst2 receptor subtypes were evaluated in
some limbic areas of PND-23 rats (n = 11) treated
with either hBPA or OIL, as described in
“Materials and Methods.” Mean values in each
brain region of the same treatment group were
analyzed using a two-tailed Student’s t-test. *p <
0.05; **p < 0.01; ***p < 0.001. 
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notable BPA influence was registered, this
time for the high-afﬁnity type of sst2 recep-
tor in the presence of Ro 15-4513 (Figure
6A). When the effects of GABA type A ago-
nists were checked in animals 23 days of age,
variations of low-afﬁnity receptors were sim-
ilar to those of PND 10 animals (Figure 7B),
whereas a marked reduction of the changes
in the high-afﬁnity type was observed again,
mostly in the presence of Ro 15-4513
(Figure 7B). 
Discussion
Investigation of the specific SRIF receptor
subtype (sst2) under the inﬂuence of the envi-
ronmental estrogen BPA made it feasible to
discern, for the ﬁrst time, the importance of
this xenoestrogen on cerebral-dependent
mechanisms that might be considered critical
for morphological aspects and neuroen-
docrine activities in the developing rat. In this
study, the binding activity of the sst2 subtype
was compared with a somewhat low dose and
a sufﬁciently high BPA dose that accounted
for, in the case of the latter dose, the alter-
ation of both body weight and reproductive
tract morphology in rodents (29,30). These
morpho-functional aspects have led
researchers to consider doses greater than
200 µg as a selective developmental toxicant
(16,28). At the brain level, the actions of both
BPA doses appeared to behave in an estro-
genic fashion, as demonstrated by the similar
Scatchard curves of [125I]-Tyr0-SRIF14 bind-
ing in the presence of 17β-estradiol (16,31).
However, it was the high dose that was associ-
ated with the shifting of the curve toward a
greater affinity of the sst2 receptor subtype.
Indeed, application of the higher BPA dose
was responsible for the evident binding capac-
ities of both afﬁnity states of the sst2 subtype
in some areas of the posterior limbic regions.
This distinction was made possible by the
binding conditions adopted in our study,
speciﬁcally a radioligand exhibiting a strong
afﬁnity for the sst2 subtype along with an ele-
vated concentration of GTP. This concentra-
tion, higher than that used in the past (22),
allowed us to explore the more extreme satu-
ration ranges of the sst2 receptor subtype. The
identiﬁcation of both high- and low-afﬁnity
states as probable targets of xenoestrogen
interactions, as shown in a previous work
(14), was also facilitated by the greater prefer-
ence of the [125I]-Tyr0-SRIF14 toward the
deglycosylated form of sst receptors, a condi-
tion typical for the sst2 subtype (13,32). 
Endocrine Disruptors • Facciolo et al.
Figure 6. BPA-dependent changes of sst2 in presence of GABA type A selective agonists in PND-10 rats.
Effects of 20 nM of the selective benzodiazepine agonists, the imidazopyridine zolpidem, or the imida-
zobenzodiazepinone Ro 15-4513 on [125I]-Tyr0-SRIF14 binding to both (A) high high-affinity and (B) low-
afﬁnity sst2 receptor binding states were tested in some limbic areas of PND 10 rats (n = 12) treated with
hBPA (400 µg/kg/day) compared with OIL-treated rats, as described in “Materials and Methods.” Values
of sst2 induced by the hBPA dose compared with OIL-treated animals in the presence of the GABA type A
selective agonists were expressed as a ratio to the same treatment groups in the absence of the selec-
tive agonists. The ratios (χ – ± SEM) were compared using ANOVA, and differences, where necessary,
were obtained by Newman-Keuls multiple range test. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 5. Competition assay. Displacement curves
of [125I]-Tyr0-SRIF14 (% of total binding) in some
limbic areas of animals treated with (A) OIL (n = 5)
and (B) hBPA (n = 5) were generated in the pres-
ence of different concentrations (5 nM–500 µM)
of selective benzodiazepine (zolpidem) and GABA
type A (isoguvacine) agonists, as described in
“Materials and Methods.” Each point represents
the mean of ﬁve separate tests. 
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The evaluation of the two afﬁnity states
of the sst2 subtype in some posterior limbic
areas of postnatal rats treated with a high
BPA dose showed that mainly the low-afﬁn-
ity state was the preferential target of this
environmental estrogen. In fact, the greater
changes occurred in hypothalamic, hip-
pocampal, and amygdalar areas that are not
only noted for a marked binding density of
the sst2 receptor subtype (22,33,34) but also
for the E2-dependent regulation of this
receptor subtype (35,36), though at different
concentrations. This was particularly evident
by the higher levels of the sst2 receptor
subtype in the Pe and RAD of PND 10 rats,
whereas an inverse trend was provided by
the VMN, Bm, and Co-Me of PND 23 ani-
mals. Whereas the major effects seemed to
occur in steroid-enriched brain regions,
studies have demonstrated that this female
sex steroid does not always require the colo-
calization of their specific steroids as in the
case of the Pe (37), indicating that perhaps
the estrogenic effects in similar areas are
accomplished by indirect means such as a
local membrane type of mechanism (2) or
through the sharing of colocalized E2 recep-
tors on GABAergic terminals of neighboring
areas (19). This relationship appears to sup-
port the strong E2-dependent modulatory
release of SRIF by GABA agonists, with the
consequent alteration of the growth hor-
mone secretion levels (38) in areas that lack
E2 receptors. Moreover, the prevalence of the
low-affinity type of sst2 receptor as a target
of the xenoestrogen, plus the major changes
occurring in the PND 10 stage, tend to
point to either a predominance of this type
of affinity state at the early developmental
stages responsible for neuronal communicat-
ing functions (39) or simply that this repre-
sents the preferred targets of BPA in an
age-independent manner.
The differences of BPA-induced actions
on the sst2 subtype were even greater in the
presence of major agonists zolpidem and
Ro 15-4513, which are specific for α1 and
α4 GABA type A receptor subunits (17), fur-
ther emphasizing the cruciality of such
receptor binding conditions for the success
of this environmental E2. That GABAergic
components are involved in the enhance-
ment of BPA-dependent sst2 levels, with the
exception of the VMN and GD, is not sur-
prising if we consider that these two receptor
systems are both widely distributed.
Moreover, the two receptor systems are not
only colocalized functionally (40,41) but
also structurally, as revealed by the identiﬁ-
cation of a novel site for sst2 on GABA type
A complex (42). However, it is worth noting
that although the two α isoforms are impli-
cated, in a similar fashion, on steroidal regu-
latory interactions (2,43), it is the latter
isoform that exerts greater BPA-induced sst2
receptor subtype changes. The lack of a con-
sistent zolpidem-dependent modulatory
action could be due to the GABA type A
receptor complex not being assembled by
this subunit isoform, as some hypothalamic
stations do not contain the α1 subunit (44).
On the other hand, it is specifically the α4
isoform that seems to be the preferred target
of steroids involved in the restoration of anx-
iolytic and analgesic states (45,46). Thus, in
line with these observations, our results seem
to further extend the participation of
α4-dependent GABAergic functions.
Taken together, these results provide for
the ﬁrst time direct evidence of BPA activi-
ties being regulated in a heterogeneous fash-
ion at the cerebral level through the
interaction of the sst2 receptor subtype at
the early developmental phases. In most
cases, BPA was responsible for greater
diminished levels of the sst2 receptor sub-
type. This accounts for the lower inhibitory
activities of this subtype, with the exception
of Pe, in which case the higher quantity of
sst2 is probably linked to the hypothalamic
area being the major site of SRIF mRNA
expression (36).
However, the sensitivity of this inter-
action appears to rely heavily on participation
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Figure 7. BPA-dependent changes of sst2 in presence of GABA type A selective agonists in PND-23 rats.
Effects of 20 nM of the selective benzodiazepine agonists, the imidazopyridine zolpidem or the imida-
zobenzodiazepinone Ro 15-4513 on [125I]-Tyr0-SRIF14 binding to both (A) high-afﬁnity and (B) low-afﬁnity
sst2 receptor binding states were tested in some limbic areas of PND-23 rats (n = 13) treated with hBPA
compared with OIL-treated rats, as described in “Materials and Methods.” Values of sst2 induced by the
hBPA dose compared with OIL-treated animals in the presence of the GABA type A selective agonists
were expressed as a ratio to the same treatment groups in the absence of the selective agonists. The
ratios (χ – ± SEM) were compared using ANOVA, and differences, where necessary, were obtained by
Newman-Keuls multiple range test. *p < 0.05; **p < 0.01; ***p < 0.001.
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of some α GABA type A receptor subunits,
in particular the α4 isoform. Observations of
the present study could provide further
insights into phenomena such as the accelera-
tion of puberty after treatment with this envi-
ronmental estrogen (47), as well as contribute
to the understanding of the steroidal influ-
ence on hypothalamic circadian pacemakers
under stress and estrous cycle (48). In the lat-
ter case, BPA could assume a prominent role,
especially because of its more recently recog-
nized feature: the capability of promoting
gene transcriptional activities necessary for the
synthesis of progesterone receptors in hypo-
thalamic neurons of ovariectomized animals
(49). Indeed it is obvious that we are still at
the beginning, but interests concerning the
type of models for studying this endocrine
disruptor are rapidly emerging. Perhaps the
exploitation of its estrogenic-like activity
might represent a potential value for the
screening of environmental E2 as agents of
congenital neural problems and memory loss
that are linked to glutamate-induced
neuronal cell death (50).
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